Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric phase II study to evaluate feasibility and efficacy of association of imatinib mesylate and zoledronic acid in patients with chronic myeloid leukaemia in cytogenetic response without molecular response after one year of imatinib mesylate monotherapy.

Trial Profile

Multicentric phase II study to evaluate feasibility and efficacy of association of imatinib mesylate and zoledronic acid in patients with chronic myeloid leukaemia in cytogenetic response without molecular response after one year of imatinib mesylate monotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2013

At a glance

  • Drugs Imatinib; Zoledronic acid
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 31 Oct 2007 Status changed from initiated to terminated
    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top